Dova Pharmaceuticals Inc. priced its underwritten public offering of 2.5 million common shares at $32 each.
The Durham, N.C.-based company expects to raise gross proceeds of about $80 million through the offering, which is expected to close Feb. 27, subject to customary closing conditions.
Dova Pharmaceuticals, which develops drugs for platelet deficiency, granted underwriters a 30-day option to buy up to an additional 375,000 at the offering price.
J.P. Morgan Securities LLC, Jefferies LLC and Evercore Group LLC are acting as joint book-running managers for the offering.
